These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18182107)

  • 1. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
    Holtz DO; Krafty RT; Mohamed-Hadley A; Zhang L; Alagkiozidis I; Leiby B; Guo W; Gimotty PA; Coukos G
    J Transl Med; 2008 Jan; 6():2. PubMed ID: 18182107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S; Laird D; Cherrington JM; Knox SJ
    Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
    Cooney MM; Tserng KY; Makar V; McPeak RJ; Ingalls ST; Dowlati A; Overmoyer B; McCrae K; Ksenich P; Lavertu P; Ivy P; Hoppel CL; Remick S
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):295-300. PubMed ID: 15538570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraising antiangiogenic therapy for breast cancer.
    Kerbel RS
    Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer.
    Janát-Amsbury MM; Yockman JW; Anderson ML; Kieback DG; Kim SW
    Anticancer Res; 2006; 26(5A):3223-8. PubMed ID: 17094433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
    Lara PN; Quinn DI; Margolin K; Meyers FJ; Longmate J; Frankel P; Mack PC; Turrell C; Valk P; Rao J; Buckley P; Wun T; Gosselin R; Galvin I; Gumerlock PH; Lenz HJ; Doroshow JH; Gandara DR;
    Clin Cancer Res; 2003 Oct; 9(13):4772-81. PubMed ID: 14581348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapies in epithelial ovarian cancer.
    Teoh DG; Secord AA
    Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibitors for the treatment of ovarian cancer.
    Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
    Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
    Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
    J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
    Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
    Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
    Hou W; Chen H; Rojas J; Sampath P; Thorne SH
    Int J Cancer; 2014 Sep; 135(5):1238-46. PubMed ID: 24474587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
    Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study.
    Lennernäs B; Albertsson P; Damber JE; Norrby K
    APMIS; 2004 Mar; 112(3):201-9. PubMed ID: 15153162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
    Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.